Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ExPRESS:2 (Experiences of Psychosis Relapse: Early Subjective Signs) Longitudinal Feasibility Study

NCT03558529 is registered in ClinicalTrials.gov with Manchester Academic Health Science Centre as lead sponsor.

NCT NCT03558529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03558529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ExPRESS:2 (Experiences of Psychosis Relapse: Early Subjective Signs) Longitudinal Feasibility Study
Lead sponsor
Manchester Academic Health Science Centre
Phase
Observational
Overall status
Completed
Start date
May 1, 2015
Completion date
April 1, 2018
Enrollment
27 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

psychosis, psychotic disorders, schizo affective disorder, schizophrenia, schizophrenia relapse